Senate Committee Grills Azar on Eli Lilly Price Hikes

International Pharmaceutical Regulatory Monitor
A A
Alex Azar, President Trump’s nominee for Secretary of Health and Human Services, emphasized his view that “drug prices are too high” to the Senate Finance Committee, even as Democrats continued to ask about his role in drug cost increases at Eli Lilly when he served as its president.

To View This Article:

Login

Subscribe To International Pharmaceutical Regulatory Monitor